Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for replacement treatment of patients with haemophilia during invasive procedures and surgery, 2nd edition, year 2020
2020
Abstract
Haemophilia A and B are rare congenital bleeding disorders. Invasive procedures and surgery can be performed safely in patients with haemophilia without inhibitors due to the availability of coagulation factors VIII and IX.
The aim of these guidelines is to summarize experience and recommendations for treatment including optimal factors VIII/IX levels during surgery, laboratory monitoring and replacement treatment duration after these procedures. A special attention is drawn to the procedures in patiens being treated by the bispecific monoclonal antibody emicizumab.